The Immunological Monitoring Core provides immunologic and biological assay support for ongoing research projects and clinical trials at the Cancer Center and the biomedical community at the University of Michigan. Services are provided in three different areas. First, simultaneous detection of numerous cytokines, chemokines, hormones and other released proteins and the related technical support are provided on a continued basis for investigators. These assays are performed with the Luminex[200] System, and via ELISA using a robotics pipetting station. Second, TAA-specific T cell response assays will be provided to investigators. These assays Include TAA-specific cytokine ELISA spot by using the AID ELISPOT Plate Reader, and TAA-specific T cell proliferation and CTL activities. Third, the Core provides time standard technical services to support clinical research protocols in the immunobiology area for Investigators who do not have standard wet laboratory space. This facility will provide the opportunity to have tissues processed and analyzed for general immune parameters, standard lymphocyte and tumor proliferation assays, as well as quantification of cytokines. These Immune assays may not nomially be available In the non-immunology laboratory, The Core also provides expert advice that helps investigators select appropriate immune assays using appropriate reagents and apply them to best advantage.

Public Health Relevance

The services provided by the immune Monitoring Core support research by investigators involved in immunological approaches to the treatment of cancer. The overall goal of this core is to extend or improve the quality of life of cancer patients through immune mechanisms.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Center Core Grants (P30)
Project #
2P30CA046592-24
Application #
8300291
Study Section
Subcommittee G - Education (NCI)
Project Start
2012-06-01
Project End
2017-05-31
Budget Start
2012-09-21
Budget End
2013-05-31
Support Year
24
Fiscal Year
2012
Total Cost
$197,538
Indirect Cost
$70,423
Name
University of Michigan Ann Arbor
Department
Type
DUNS #
073133571
City
Ann Arbor
State
MI
Country
United States
Zip Code
48109
Khoriaty, Rami; Hesketh, Geoffrey G; Bernard, Amélie et al. (2018) Functions of the COPII gene paralogs SEC23A and SEC23B are interchangeable in vivo. Proc Natl Acad Sci U S A 115:E7748-E7757
Katz, Steven J; Ward, Kevin C; Hamilton, Ann S et al. (2018) Gaps in Receipt of Clinically Indicated Genetic Counseling After Diagnosis of Breast Cancer. J Clin Oncol 36:1218-1224
Ulintz, Peter J; Greenson, Joel K; Wu, Rong et al. (2018) Lymph Node Metastases in Colon Cancer Are Polyclonal. Clin Cancer Res 24:2214-2224
Qin, Tingting; Zhang, Yanxiao; Zarins, Katie R et al. (2018) Expressed HNSCC variants by HPV-status in a well-characterized Michigan cohort. Sci Rep 8:11458
Xu, Shilin; Aguilar, Angelo; Xu, Tianfeng et al. (2018) Design of the First-in-Class, Highly Potent Irreversible Inhibitor Targeting the Menin-MLL Protein-Protein Interaction. Angew Chem Int Ed Engl 57:1601-1605
Crespo, Joel; Wu, Ke; Li, Wei et al. (2018) Human Naive T Cells Express Functional CXCL8 and Promote Tumorigenesis. J Immunol 201:814-820
Manohar, Poorni M; Beesley, Lauren J; Bellile, Emily L et al. (2018) Prognostic Value of FDG-PET/CT Metabolic Parameters in Metastatic Radioiodine-Refractory Differentiated Thyroid Cancer. Clin Nucl Med 43:641-647
Hawley, Sarah T; Li, Yun; An, Lawrence C et al. (2018) Improving Breast Cancer Surgical Treatment Decision Making: The iCanDecide Randomized Clinical Trial. J Clin Oncol 36:659-666
Salami, Simpa S; Hovelson, Daniel H; Kaplan, Jeremy B et al. (2018) Transcriptomic heterogeneity in multifocal prostate cancer. JCI Insight 3:
Smith, Joshua; Kulkarni, Aditi; Birkeland, Andrew C et al. (2018) Whole-Exome Sequencing of Sinonasal Small Cell Carcinoma Arising within a Papillary Schneiderian Carcinoma In Situ. Otolaryngol Head Neck Surg 159:859-865

Showing the most recent 10 out of 1493 publications